Cardio Diagnostics Holdings (CDIO) Net Cash Flow (2021 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Net Cash Flow of $2.0 million for Q1 2026, up 258.0% sequentially from -$1.2 million in Q4 2025, and up 5.65% YoY from $1.9 million in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Net Cash Flow (2021 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Net Cash Flow for 6 years, with the latest figure at $2.0 million in Q1 2026.
- Quarterly Net Cash Flow rose 5.65% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.6 million (down 132.14% YoY) and the FY2025 annual result came in at -$2.7 million, down 141.52% from the prior year.
- Net Cash Flow improved to $2.0 million in Q1 2026 per CDIO's latest filing, from -$1.2 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $9.3 million in Q2 2022 and troughed at -$4.8 million in Q4 2022.
- A 5-year average of $386132.6 and a median of -$253020.0 in 2024 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 27198.64% in 2022, down 7289.53% in 2022.
- Over 5 years, Net Cash Flow stood at -$4.8 million in 2022, then soared by 51.59% to -$2.3 million in 2023, then surged by 349.13% to $5.8 million in 2024, then sank by 121.29% to -$1.2 million in 2025, then surged by 258.0% to $2.0 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $2.0 million, -$1.2 million, and -$1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 225.59 Mn |
| 10 | Cardio Diagnostics Holdings | 6.13 Mn | 539,403.63 | - | -1.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.49 Mn |
| Jun 30, 2026 | -1.49 Mn |
| Mar 31, 2026 | 1.97 Mn |
| Mar 31, 2026 | 1.97 Mn |
| Dec 31, 2025 | -1.24 Mn |
| Dec 31, 2025 | -1.24 Mn |
| Sep 30, 2025 | -1.61 Mn |
| Sep 30, 2025 | -1.61 Mn |
| Jun 30, 2025 | -1.72 Mn |
| Jun 30, 2025 | -1.72 Mn |
| Mar 31, 2025 | 1.86 Mn |
| Mar 31, 2025 | 1.86 Mn |
| Dec 31, 2024 | 5.84 Mn |
| Dec 31, 2024 | 5.84 Mn |
| Sep 30, 2024 | 672,471.00 |
| Sep 30, 2024 | 672,471.00 |
| Jun 30, 2024 | -253,020.00 |
| Jun 30, 2024 | -253,020.00 |
| Mar 31, 2024 | 279,616.00 |
| Mar 31, 2024 | 279,616.00 |